medigraphic.com

2025, Number 4

<< Back Next >>

Enf Infec Microbiol 2025; 45 (4)

Neonatal pneumonia due to MDR Pseudomonas aeruginosa

Galván-Contreras R, Juárez-Vilches S, Mendoza-Ciprés H, Calva-Hernández JV, Solórzano-Santos F, Villalobos-Alcázar G

Language: Spanish
References: 16
Page: 207-211
PDF size: 170.06 Kb.


ABSTRACT

Pseudomonas aeruginosa is one of the main etiological agents in respiratory tract infections, especially in patients undergoing mechanical ventilation in neonatal intensive care units. The dissemination of high-risk Pseudomonas aeruginosa clones, with multidrug-resistant (MDR) and extensively drug-resistant (XDR) characteristics, has been reported in hospitals worldwide.
We present the case of a newborn (NB) at 37.1 weeks of gestation (WG), delivered by cesarean section to an adolescent mother (G1), with a prenatal diagnosis of omphalocele and a single umbilical artery. At birth, the infant required resuscitation and stage III ventilation. Due to his condition, he was admitted to the neonatal intensive care unit (NICU).During stay in the NICU, he developed pneumonia; Pseudomonas aeruginosa, resistant to multiple antimicrobials but susceptible only to aminoglycosides (amikacin, gentamicin), was isolated from bronchial secretion culture. The patient was treated with amikacin and ceftazidime.


REFERENCES

  1. “Antimicrobial resistance c. Global burden of bacterialantimicrobial resistance in 2019: a systematic analysis”,Lancet, 2022, 399:629-655.

  2. Centers for Disease Control and Prevention (cdc), “Antibioticresistance threats in the United States, 2019”,Atlanta, GA, U.S. Department of Health and HumanServices, cdc, 2019.

  3. Li, C., Claeys, K., Justo, J.A. y Heil, E.L., “No crystal ball?Using risk factors and scoring systems to predict extended-spectrum beta-lactamase producing enterobacterales(esbl-e) and carbapenem-resistant enterobacterales (cre)infections”, Curr Infect Dis Rep, 2022, 24: 147-158.

  4. Hernández-Cortez, C., Luna-Pineda, V.M., Castro-Escarpulli,G., Lozano-Medina, L. y Luna-Arias, J.P., “Prevalencia debacterias multirresistentes en una unidad de cuidadosintensivos neonatales en México”, Bol Med HospInfant Mex, 2022, 79 (2): 105-112. Disponible en:https://www.sciencedirect.com/science/article/pii/S2444347322000123Centers for.

  5. “Disease control and prevention. Pneumonia (ventilator-associated [vap] and non-ventilator-associated[pneu]) event”, Atlanta, GA, cdc, 2023. Disponible en:https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf.

  6. Heil, E.L., Bork, J.T., Abbo, L.M. et al., “Optimizing themanagement of uncomplicated gram-negative bloodstreaminfections: consensus guidance using a modifieddelphi process”, Open Forum Infect Dis, 2021, 8:ofab434.

  7. Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J.,Van Duin, D. y Clancy, C.J., “Infectious Diseases Societyof America guidance on the treatment of antimicrobial-resistant gram-negative infections”, Clin Infect Dis,2022, 74 (12): 2111-2115.

  8. Bush, K. y Bradford, P.A., “Epidemiology of beta-lactamase-producing pathogens”, Clin Microbiol Rev, 2020,33: e00047-19.

  9. Hareza, D., Cosgrove, S.E., Simner, P.J. et al., “Is carbapenemtherapy necessary for the treatment of non-ctx-mesbl-producing enterobacterales bloodstream infections?”,Clin Infect Dis, 2024, 78: 1103-1110.

  10. Soto, C.L., Hsu, A.J., Lee, J.H. et al., “Identifying effectivedurations of antibiotic therapy for the treatment ofcarbapenem-resistant enterobacterales bloodstream infections:a multicenter observational study”, Clin InfectDis, 2023, 78: 27-30.

  11. Gupta, K., Hooton, T.M., Naber, K.G. et al., “Internationalclinical practice guidelines for the treatment of acuteuncomplicated cystitis and pyelonephritis in women:a 2010 update by the Infectious Diseases Society ofAmerica and the European Society for Microbiology andInfectious Diseases”, Clin Infect Dis, 2011, 52: e103-120.

  12. Tamma, P.D., Smith, T.T., Adebayo, A. et al., “Prevalenceof bla ctx-m genes in gram-negative bloodstream isolatesacross 66 hospitals in the United States”, J ClinMicrobiol, 2021, 59: e00127-21.

  13. Castanheira, M., Kimbrough, J.H., DeVries, S., Mendes,R.E. y Sader, H.S., “Trends of beta-lactamase occurrenceamong Escherichia coli and Klebsiella pneumoniaein United States hospitals during a 5-year period andactivity of antimicrobial agents against isolates stratifiedby beta-lactamase type”, Open Forum Infect Dis, 2023,10: ofad038.

  14. Robberts, F.J., Kohner, P.C. y Patel, R., “Unreliableextended-spectrum beta-lactamase detection in thepresence of plasmid-mediated ampc in Escherichia coliclinical isolates”, J Clin Microbiol, 2009, 47: 358-361.

  15. Zhang, X., Zhang, D., Zhou, D., Zheng, S., Li, S., Hou, Q.,Li, G. y Han, H., “A comprehensive review of the pathogenicmechanisms of Pseudomonas aeruginosa: synergisticeffects of virulence factors, quorum sensing, andbiofilm formation”, Front Microbiol, 2025, 16: 1619626.

  16. Kumar, S., Ray, P. y Sahana, R., “Emerging trend of multidrug-resistant organisms causing sepsis in ventilatednewborns”, Ann Afr Med, 2025, 24 (3): 604-609.




2020     |     www.medigraphic.com